{"id":"tenofovir-disoproxil-emtricitabine-efavirenz","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Dizziness and CNS effects"},{"rate":"10-20","effect":"Rash"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Elevated liver enzymes"},{"rate":"1-5","effect":"Renal dysfunction (tenofovir-related)"},{"rate":"variable","effect":"Bone density loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tenofovir disoproxil and emtricitabine are nucleoside reverse transcriptase inhibitors (NRTIs) that compete with natural nucleotides to terminate viral DNA chain elongation. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and blocks its catalytic activity. Together, these three agents suppress HIV replication by targeting the same enzyme through complementary mechanisms.","oneSentence":"This combination inhibits HIV reverse transcriptase and integrase through three antiretroviral agents working synergistically to block viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:40.978Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"HIV-1 prevention (pre-exposure prophylaxis, PrEP)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT02591420","phase":"PHASE1","title":"Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT01778413","phase":"PHASE4","title":"Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-06-03","conditions":"HIV","enrollment":61},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT02652260","phase":"PHASE2","title":"Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-03-04","conditions":"HIV-1, Central Nervous System","enrollment":86},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT02403674","phase":"PHASE3","title":"Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":734},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT02722421","phase":"PHASE2","title":"Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-04-06","conditions":"HIV, Contraception","enrollment":28},{"nctId":"NCT06619288","phase":"","title":"Good-first: B/F/TAF As First-line ART","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-07-01","conditions":"HIV Infection","enrollment":630},{"nctId":"NCT03502005","phase":"PHASE4","title":"Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1","status":"COMPLETED","sponsor":"Midland Research Group, Inc.","startDate":"2018-03-01","conditions":"Human Immunodeficiency Virus","enrollment":100},{"nctId":"NCT01789879","phase":"PHASE2","title":"A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2014-03-04","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT02475915","phase":"PHASE1, PHASE2","title":"Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2015-01","conditions":"Acute HIV Infection","enrollment":15},{"nctId":"NCT00775606","phase":"PHASE4","title":"Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2008-10","conditions":"Acquired Immune Deficiency Syndrome","enrollment":15},{"nctId":"NCT03122262","phase":"PHASE3","title":"ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2017-01-16","conditions":"HIV-1 Infection","enrollment":1110},{"nctId":"NCT04296695","phase":"PHASE4","title":"Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":250},{"nctId":"NCT03532425","phase":"PHASE4","title":"B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2018-10-29","conditions":"HIV-1-infection","enrollment":28},{"nctId":"NCT03048422","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-19","conditions":"HIV Infections","enrollment":643},{"nctId":"NCT01815580","phase":"PHASE4","title":"HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-07","conditions":"HIV","enrollment":225},{"nctId":"NCT04424264","phase":"PHASE1","title":"The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2019-12-05","conditions":"HIV-1-infection, Tuberculosis","enrollment":18},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01147107","phase":"PHASE4","title":"Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2014-02","conditions":"Hepatitis C, Chronic, HIV Infection","enrollment":80},{"nctId":"NCT00344760","phase":"PHASE4","title":"A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2005-01","conditions":"HIV Infections","enrollment":2},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT01709084","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-10-02","conditions":"Human Immunodeficiency Virus-type 1 Infection","enrollment":426},{"nctId":"NCT02057796","phase":"PHASE4","title":"Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-09","conditions":"HIV-1 Infection","enrollment":1050},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT03405194","phase":"NA","title":"Same-Day Treatment With Genvoya vs. EFV/TDF/3TC","status":"WITHDRAWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2018-05-01","conditions":"HIV/AIDS","enrollment":""},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01011413","phase":"PHASE3","title":"Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2011-08","conditions":"HIV Infections","enrollment":636},{"nctId":"NCT03595709","phase":"PHASE3","title":"Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan","status":"COMPLETED","sponsor":"Yu-Jay Corp.","startDate":"2018-12-06","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT01641809","phase":"PHASE2","title":"Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-08-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":244},{"nctId":"NCT02345226","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-26","conditions":"HIV-1 Infection","enrollment":881},{"nctId":"NCT01352117","phase":"PHASE3","title":"Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11-18","conditions":"HIV-1 Infection, Kaposi's Sarcoma","enrollment":192},{"nctId":"NCT01293123","phase":"NA","title":"Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2011-12","conditions":"HIV","enrollment":2},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT00335322","phase":"PHASE4","title":"ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2007-02","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":329},{"nctId":"NCT01632891","phase":"PHASE1, PHASE2","title":"Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-01-10","conditions":"HIV-1 Infection, Pf Subclinical Parasitemia","enrollment":52},{"nctId":"NCT01632345","phase":"PHASE2","title":"A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-12","conditions":"HIV Infections","enrollment":342},{"nctId":"NCT03251690","phase":"NA","title":"Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2016-10-27","conditions":"Anti-Retroviral Agents, Efavirenz, HIV-1-infection","enrollment":246},{"nctId":"NCT02946762","phase":"NA","title":"TasP in Correctional Facilities","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-02-01","conditions":"HIV, Tuberculosis","enrollment":419},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00442962","phase":"PHASE4","title":"HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2007-05","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT01403051","phase":"PHASE2","title":"High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-09","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT00118898","phase":"PHASE3","title":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-09","conditions":"HIV Infections","enrollment":1864},{"nctId":"NCT00108862","phase":"PHASE4","title":"Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2006-08","conditions":"HIV Infection, Tuberculosis","enrollment":809},{"nctId":"NCT00084136","phase":"PHASE4","title":"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-05","conditions":"HIV Infections","enrollment":1571},{"nctId":"NCT02415595","phase":"PHASE2","title":"Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2015-05-12","conditions":"Infection, Human Immunodeficiency Virus","enrollment":210},{"nctId":"NCT02042001","phase":"PHASE4","title":"Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Gerardo di Monza","startDate":"2015-07-01","conditions":"Impaired Cognition, Depression/Anxiety, Poor Quality Sleep","enrollment":74},{"nctId":"NCT01263015","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-02-01","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":844},{"nctId":"NCT01891799","phase":"","title":"Swaziland Safe Generations","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-08","conditions":"HIV/AIDS","enrollment":2518},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT00951015","phase":"PHASE2","title":"A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-07-30","conditions":"Infection, Human Immunodeficiency Virus","enrollment":208},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT01935830","phase":"EARLY_PHASE1","title":"LAAM-HAART PET Imaging","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT01231555","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-11-18","conditions":"Infection, Human Immunodeficiency Virus","enrollment":23},{"nctId":"NCT02499874","phase":"PHASE1","title":"SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08","conditions":"HIV","enrollment":26},{"nctId":"NCT03309566","phase":"PHASE4","title":"Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir","status":"COMPLETED","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2016-09-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT00414635","phase":"PHASE4","title":"FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2006-08","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT02529059","phase":"PHASE4","title":"SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-11","conditions":"HIV","enrollment":40},{"nctId":"NCT02269462","phase":"","title":"A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and Lactation","status":"COMPLETED","sponsor":"Adeniyi Olagunju","startDate":"2012-12","conditions":"HIV, Pregnancy, Breastfeeding","enrollment":460},{"nctId":"NCT01929759","phase":"NA","title":"Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"HIV Disease","enrollment":10},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT02832778","phase":"PHASE1","title":"Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2016-11-21","conditions":"HIV","enrollment":35},{"nctId":"NCT02547844","phase":"PHASE4","title":"Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-09","conditions":"HIV-1","enrollment":30},{"nctId":"NCT01173510","phase":"PHASE4","title":"A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells","status":"WITHDRAWN","sponsor":"Community Research Initiative of New England","startDate":"2010-08-23","conditions":"HIV Infections, Acquired Immune Deficiency Syndrome","enrollment":""},{"nctId":"NCT00924898","phase":"PHASE4","title":"Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-01","conditions":"Acute HIV Infection, HIV Infections","enrollment":92},{"nctId":"NCT02447016","phase":"PHASE4","title":"Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2015-05","conditions":"HIV","enrollment":25},{"nctId":"NCT00369941","phase":"PHASE3","title":"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08","conditions":"HIV Infections","enrollment":566},{"nctId":"NCT01040091","phase":"PHASE1","title":"Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-12","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT01509508","phase":"NA","title":"Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-03","conditions":"HIV Infection","enrollment":28153},{"nctId":"NCT02827643","phase":"NA","title":"Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2016-06","conditions":"Bone Density","enrollment":48},{"nctId":"NCT00734344","phase":"NA","title":"Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2008-09","conditions":"Acute HIV Infection","enrollment":18},{"nctId":"NCT00540449","phase":"PHASE3","title":"TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-05","conditions":"HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1","enrollment":694},{"nctId":"NCT02283060","phase":"PHASE4","title":"Sleep and Cognition After Atripla to Stribild Switch","status":"UNKNOWN","sponsor":"University of Hawaii","startDate":"2014-09","conditions":"HIV","enrollment":30},{"nctId":"NCT01479634","phase":"NA","title":"Early HIV Therapy in Patients With High CD4 Cell Counts","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-10","conditions":"HIV","enrollment":279},{"nctId":"NCT01515813","phase":"PHASE2","title":"Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation","status":"WITHDRAWN","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11","conditions":"HIV-1 Infection","enrollment":""},{"nctId":"NCT02157311","phase":"PHASE3","title":"4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-07","conditions":"HIV-1 Infection","enrollment":100},{"nctId":"NCT01495702","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":439},{"nctId":"NCT01322932","phase":"","title":"Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey","status":"COMPLETED","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2010-07","conditions":"HIV Infection","enrollment":95},{"nctId":"NCT01095796","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03","conditions":"HIV, HIV Infections","enrollment":707},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT00863668","phase":"NA","title":"Raltegravir Activity In Lymphoid Tissues","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2009-03","conditions":"HIV Infection, HIV Infections","enrollment":""},{"nctId":"NCT00984152","phase":"PHASE3","title":"Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2011-06","conditions":"HIV-1 Infections","enrollment":""},{"nctId":"NCT00737724","phase":"NA","title":"Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment","status":"TERMINATED","sponsor":"Instituto Nacional de Enfermedades Respiratorias","startDate":"2008-03","conditions":"HIV, AIDS, Tuberculosis","enrollment":63},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01690403","phase":"PHASE1","title":"Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-12","conditions":"Tuberculosis","enrollment":25},{"nctId":"NCT01309243","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-02","conditions":"HIV-1 Infection","enrollment":799},{"nctId":"NCT01180075","phase":"","title":"Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-05","conditions":"Human Immunodeficiency Virus","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Atripla"],"phase":"marketed","status":"active","brandName":"Tenofovir disoproxil/emtricitabine/efavirenz","genericName":"Tenofovir disoproxil/emtricitabine/efavirenz","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV reverse transcriptase and integrase through three antiretroviral agents working synergistically to block viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 prevention (pre-exposure prophylaxis, PrEP).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}